Surgical Septal Myectomy ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 58 | Hypertrophic cardiomyopathy | 1 |
58. Hypertrophic cardiomyopathy
Clinical trials : 119 / Drugs : 163 - (DrugBank : 45) / Drug target genes : 48 - Drug target pathways : 161
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04684290 (ClinicalTrials.gov) | June 30, 2021 | 16/11/2020 | Surgical Septal Myectomy vs Percutaneous Transluminal Alcohol Septal Ablation in Patients With Hypertrophic Obstructive Cardiomyopathy | Surgical Septal Myectomy Versus Percutaneous Transluminal Alcohol Septal Ablation in Patients With Hypertrophic Obstructive Cardiomyopathy | Hypertrophic Cardiomyopathy | Procedure: Alcohol Septal Ablation;Procedure: Surgical Septal Myectomy | St. Antonius Hospital | Erasmus Medical Center | Recruiting | 40 Years | 75 Years | All | 100 | N/A | Netherlands |